GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1ME34) » Definitions » Other Stockholders Equity

BeiGene (BSP:B1ME34) Other Stockholders Equity : R$-0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeiGene Other Stockholders Equity?

BeiGene's Other Stockholders Equity for the quarter that ended in Dec. 2024 was R$-0 Mil.

BeiGene's quarterly Other Stockholders Equity increased from Jun. 2024 (R$0 Mil) to Sep. 2024 (R$0 Mil) but then declined from Sep. 2024 (R$0 Mil) to Dec. 2024 (R$-0 Mil).

BeiGene's annual Other Stockholders Equity increased from Dec. 2022 (R$0 Mil) to Dec. 2023 (R$0 Mil) but then declined from Dec. 2023 (R$0 Mil) to Dec. 2024 (R$-0 Mil).


BeiGene Other Stockholders Equity Historical Data

The historical data trend for BeiGene's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Other Stockholders Equity Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BeiGene Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


BeiGene Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of BeiGene's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines